Innate Pharma (IPHA) — Cash Flow Quality Index
Latest as of June 2023:
-6.67x
Innate Pharma (IPHA) has a Cash Flow Quality Index of -6.67x as of June 2023. Operating cash flow of $-11.46 Million is below net income of $1.72 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore IPHA cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
-6.67x
Operating CF / Net Income
Operating Cash Flow
$-11.46 Million
USD
Net Income
$1.72 Million
USD
Data as of
Jun 2023
Most recent filing
Innate Pharma Cash Flow Quality Index (2016–2018)
Historical Cash Flow Quality Index for Innate Pharma across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see IPHA cash flow metrics.
Annual Cash Flow Quality Index for Innate Pharma (2016–2018)
Year-by-year earnings quality comparison for Innate Pharma.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2018 | -10.67x | $-32.53 Million | $3.05 Million | ▼ -266.0% |
| 2016 | -2.92x | $-36.85 Million | $12.64 Million | — |
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.